226 related articles for article (PubMed ID: 19445902)
21. Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
Linares OA; Fudin J; Daly AL; Boston RC
Clin J Pain; 2015 Dec; 31(12):1026-35. PubMed ID: 25621429
[TBL] [Abstract][Full Text] [Related]
22. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu AM; Idle JR; Byrd LG; Krausz KW; Küpfer A; Gonzalez FJ
Pharmacogenetics; 2003 Mar; 13(3):173-81. PubMed ID: 12618595
[TBL] [Abstract][Full Text] [Related]
23. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
24. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
Thomas CD; Mosley SA; Kim S; Lingineni K; El Rouby N; Langaee TY; Gong Y; Wang D; Schmidt SO; Binkley PF; Estores DS; Feng K; Kim H; Kinjo M; Li Z; Fang L; Chapman AB; Cooper-DeHoff RM; Gums JG; Hamadeh IS; Zhao L; Schmidt S; Frye RF; Johnson JA; Cavallari LH
CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):678-685. PubMed ID: 33067866
[TBL] [Abstract][Full Text] [Related]
25. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
[TBL] [Abstract][Full Text] [Related]
26. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
Storelli F; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid NA; Johnson JA
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
[TBL] [Abstract][Full Text] [Related]
28. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
[TBL] [Abstract][Full Text] [Related]
29. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes.
Li L; Pan RM; Porter TD; Jensen NS; Silber P; Russo G; Tine JA; Heim J; Ring B; Wedlund PJ
Drug Metab Dispos; 2006 Aug; 34(8):1411-6. PubMed ID: 16679388
[TBL] [Abstract][Full Text] [Related]
30. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
[TBL] [Abstract][Full Text] [Related]
31. Metabolism and clinical pharmacokinetics of 2-methyl-n-(2'-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1'-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools.
Sawant Basak A; Byon W; Tseng-Lovering E; Funk C; Wood L; Lin C; Delnomdedieu M; Verhoest P; Parikh V; Cox LM; Miller E; Gao H; Obach RS
Xenobiotica; 2014 May; 44(5):438-54. PubMed ID: 24304147
[TBL] [Abstract][Full Text] [Related]
32. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.
Men X; Taylor ZL; Marshe VS; Blumberger DM; Karp JF; Kennedy JL; Lenze EJ; Reynolds CF; Stefan C; Mulsant BH; Ramsey LB; Müller DJ
Clin Pharmacol Ther; 2024 May; 115(5):1065-1074. PubMed ID: 38284409
[TBL] [Abstract][Full Text] [Related]
34. Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype-phenotype translation.
Frederiksen T
Basic Clin Pharmacol Toxicol; 2023 Aug; 133(2):113-123. PubMed ID: 37221697
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
36. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.
Ito T; Kato M; Chiba K; Okazaki O; Sugiyama Y
Drug Metab Pharmacokinet; 2010; 25(3):243-53. PubMed ID: 20610883
[TBL] [Abstract][Full Text] [Related]
37. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
38. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
39. Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors.
Gressier F; Verstuyft C; Hardy P; Becquemont L; Corruble E
J Neural Transm (Vienna); 2015 Jan; 122(1):35-42. PubMed ID: 25047911
[TBL] [Abstract][Full Text] [Related]
40. Interspecies metabolic diversity of harmaline and harmine in in vitro 11 mammalian liver microsomes.
Li S; Teng L; Liu W; Cheng X; Jiang B; Wang Z; Wang C
Drug Test Anal; 2017 May; 9(5):754-768. PubMed ID: 27377954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
